Erythema induratum: a case of mistaken identity

Gary Y J Chew, John W Quin and Christopher Henderson
Med J Aust 2005; 183 (10): 534. || doi: 10.5694/j.1326-5377.2005.tb07156.x
Published online: 21 November 2005

Clinical record

A 29-year-old Vietnamese woman who had migrated to Australia 5 years previously was referred with a 2-month history of erythematous painful nodules on her thighs and left buttock, the largest of which measured 3 cm × 4 cm. There was no history of recent infections or previous exposure to tuberculosis. She denied any symptoms of inflammatory bowel disease, vasculitis or connective tissue disease. Examination disclosed no abnormalities such as lymphadenopathy, hepatosplenomegaly or synovitis. A chest x-ray was normal. Blood tests showed a total white cell count of 7.3 × 109/L, haemoglobin level of 133 g/L, platelet count of 295 × 109/L and an erythrocyte sedimentation rate of 11 mm/h. No antinuclear antibodies or antineutrophil cytoplasmic antibodies were detected. Liver and thyroid function tests and coagulation studies were all normal.

A working diagnosis of erythema nodosum was made, and the patient was commenced on naproxen. When treatment with naproxen was unsuccessful after 4 weeks, she was commenced on 45 mg (1 mg/kg) of prednisolone daily. As she showed only a partial response to prednisolone, a deep incisional biopsy of a lesion was performed. It revealed a granulomatous lobular panniculitis with necrosis (Box), consistent with erythema induratum (EI). There were no visible mycobacteria or fungi on staining. A subsequent Mantoux test was strongly positive, while a polymerase chain reaction test for Mycobacterium tuberculosis DNA performed on the paraffin-embedded tissue was negative. The patient was commenced on a 6-month course of quadruple antituberculous directly observed therapy, consisting of rifampicin, isoniazid, pyrazinamide and ethambutol, together with pyridoxine, while the prednisolone dose was quickly tapered and ceased. Within 2 months, the cutaneous lesions had resolved, and had not recurred a month after the completion of antituberculous therapy.

Bazin1 first described erythema induratum (EI) in 1861 to illustrate chronic, painful, violaceous, indurated and occasionally ulcerative nodules that occurred predominantly on the lower limbs of patients (mainly women) with tuberculin hypersensitivity. Its appearance can easily be confused with erythema nodosum, polyarteritis nodosa or perniosis.

The diagnosis of EI could easily have been missed, as the cutaneous lesions were similar to those characteristic of erythema nodosum. In addition, there was a partial response to corticosteroids. A diagnosis of EI is based on cutaneous characteristics, a positive Mantoux test, evidence of tuberculosis and histological findings.2 The diagnosis of EI in this patient was established with three of the four criteria. Furthermore, the patient responded clinically to antituberculous therapy.

The negative polymerase chain reaction (PCR) result is not surprising. In other studies, only 56%–88% of patients previously diagnosed with cutaneous tuberculosis had a positive PCR result using the IS6110 primer.2,3 Schneider et al4 found a positive PCR result in only 5 of 20 patients with EI. Shimizu et al5 failed to isolate Mycobacterium tuberculosis by either culturing cutaneous EI tissue or inoculating the tissue into guinea pigs. The association of EI with tuberculosis is still a matter of debate. Some have considered EI to be a type III or type IV hypersensitivity reaction to M. tuberculosis antigens.6 This may explain the patient’s partial response to corticosteroids.

Lessons from practice

  • Erythema induratum (EI) can easily be mistaken for erythema nodosum, perniosis or cutaneous polyarteritis nodosa.

  • The failure to detect Mycobacterium tuberculosis on microscopy or by a polymerase chain reaction test on the biopsy specimen does not exclude the diagnosis.

  • EI lesions can resolve with corticosteroid therapy, which may lead to a misdiagnosis of erythema nodosum.

  • EI should be treated with antituberculous therapy.

Histological section of subcutaneous tissue from one of the nodules

The lower-power image shows florid inflammatory changes involving fat lobules (L) with thickening of lobular septa (S), consistent with a florid, predominantly lobular, panniculitis. The higher-power image (inset) shows a classical combination of granulomatous inflammation (G) and eosinophilic granular fat necrosis (N).

  • Gary Y J Chew1
  • John W Quin2
  • Christopher Henderson3

  • 1 Department of Immunology, Liverpool Hospital, NSW.
  • 2 South Western Sydney Area Pathology Service, Liverpool, NSW.


Competing interests:

None identified.

  • 1. Bazin E. Extrait des leçons théoriques et cliniques sur le scrofula. 2nd ed. Paris: Delahaye, 1861.
  • 2. Jacinto SS, Nograles KB. Erythema induratum of Bazin: role of polymerase chain reaction in diagnosis. Int J Dermatol 2003; 42: 380-381.
  • 3. Tan SH, Tan HH, Sun YJ, Goh CL. Clinical utility of polymerase chain reaction in the detection of Mycobacterium tuberculosis in different types of cutaneous tuberculosis and tuberculids. Ann Acad Med Singapore 2001; 30: 3-10.
  • 4. Schneider JW, Geiger DH, Rossouw HF, et al. Mycobacterium tuberculosis DNA in erythema induratum of Bazin. Lancet 1993; 342: 747-748.
  • 5. Shimizu A, Takahashi I, Negishi A, et al. The close association of lymphadenitis and erythema induratum of Bazin in Japanese patients. Dermatology 2003; 207: 426-427.
  • 6. Kuramoto Y, Aiba S, Tagami H. Erythema induratum of Bazin as a type of tuberculid. J Am Acad Dermatol 1990; 22: 612-616.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.